Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CT 071

Next Previous
X
Search
Drug Profile

CT 071

Alternative Names: CT-071; GPRC5D targeted CAR T cell therapy - CARsgen Therapeutics

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CARsgen
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Leukaemia; Multiple myeloma

Most Recent Events

  • 15 Jun 2024 Pharmacokinetics, efficacy and adverse events data from a phase 0 trial in Multiple myeloma and Leukemia presented the 29th Annual Congress of the European Hematology Association (EHA-2024)
  • 06 Jun 2024 Phase-0 for Multiple myeloma (Newly diagnosed) in China (Parenteral) (NCT06407947)
  • 09 May 2024 CARsgen Therapeutics plans a phase 0 trial for Multiple myeloma (Newly diagnosed) (Parenteral, Infusion) in May 2024 (NCT06407947)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top